FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Kulipa Secures $62M to Enhance Stablecoin Card Issuing Infrastructure

Funding aims to strengthen cryptocurrency card services in the growing fintech market.Highlights: Kulipa raises $62M to enhance its...
FinTech

Visa Launches AI-Powered Dispute Resolution Tools

New tools aim to streamline resolution of payment disputes.Highlights: Visa introduces AI tools for payment dispute resolution.The new...
FinTech

UK Fintechs Vibepay and SmartLayer Shut Down

Both companies cease operations amidst challenging market conditions.Highlights: Vibepay and SmartLayer have officially ceased operations.The closures are attributed...
FinTech

Visa and Ramp Boost Bill Pay Automation with Agentic AI

New integration aims to streamline corporate expense management processes.Highlights: Visa and Ramp announce partnership to automate corporate bill...